Request for Proposal:  Neuroscience Assets in Lead Generation Stage

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited Neuroscience Drug Discovery Unit is searching for assets in Lead Generation stage available for out-licensing or partnerships, which may enhance our pipeline. The initial step may be for Takeda to ask for asset sharing to perform profiling.

  • Application due date: February 28, 2023

Area of interest

  • Indications of interest
    • Amyotrophic lateral sclerosis (ALS)
    • Frontotemporal lobar degeneration (FTLD)
    • Alzheimer’s disease (AD)
    • Parkinson’s disease (PD)
    • Multiple system atrophy (MSA)
    • Down syndrome with Alzheimer’s disease
    • Cerebral amyloid angiopathy (CAA)
    • Huntington’s disease (HD)
    • Hereditary ataxias
    • Spinal bulbar muscular atrophy (SBMA)
    • Muscular dystrophies (DM1, FSHD, DMD)
    • Charcot-Marie-Tooth disease (CMT)
    • Developmental and epileptic encephalopathies
  • Any therapeutic modality may be used (e.g. small molecules, antibodies, nucleic acids, etc.) as long as it is rationally acceptable
  • Asset should have human/patient-based therapeutic rationale addressing the current unmet needs of the potential target population and unique selling point versus competitor assets targeting same indication or mechanism
  • Some specific mechanisms of interest are;
    • Key autonomous and non-autonomous disease-relevant pathways including aberrant glial cells in neurodegenerative disorders
    • Cellular senescence in neurodegenerative disorders
    • Disease-relevant stress granules, liquid-liquid phase separation
    • Novel therapeutic approaches related to autophagy and mitophagy
    • Targets or therapeutic hypothesis established from patient-based findings for neurodegeneration (e.g. approaches addressing sleep/circadian rhythm, waste clearance, BBB integrity, anti-chronic inflammation, organelle homeostasis, DNA damage)
    • Innovative therapeutic approaches for signature features of genetic neurological disorders including abnormal DNA/RNA structures, RNA splicing and protein production widely observed in rare/intractable neurological diseases, somatic instability
  • Lead Generation stage assets should meet the following
    • Screening or initial lead design is completed
    • Key proof of mechanism/proof of concept data in relation to target or therapeutic hypothesis has been obtained using such lead candidates
    • Assays for further asset selection and optimization is established
    • No critical on-target safety/toxicity issues have been identified and current safety data supports further development of leads
    • Patent strategy is available

Area of “No” interest

  • Indications which are out of focus are: multiple sclerosis, acute ischemic stroke, traumatic brain injury, cerebral thrombosis, cerebral hemorrhage
  • Mechanisms which are out of focus are: dopaminergic agents for Parkinson’s disease, palliative treatments for hereditary neurological diseases such as anti-convulsant for developmental and epileptic encephalopathies

  • Application due date: February 28, 2023

About this RFP, please Click here.

Please note that Takeda Pharmaceutical Company will not be able to respond to direct inquiries.

Japan Technology Group, Inc.